If after both oral (PO) and subcutaneous (SQ) methotrexate fail to achieve disease control, and there are poor prognostic factors or patient preference, the next step may involve:
a) Adding a biologic DMARD
b) Switching to a different conventional DMARD
c) Continuing methotrexate at a higher dose
d) Initiating a targeted synthetic DMARD